Identification | More | [Name]
Halobetasol propionate | [CAS]
66852-54-8 | [Synonyms]
21-chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate HALOBETASOL PROPIONATE ulobetasol propionate Halobetasol 6 alpha-fluoroclobetasol 17-propionate 21-Chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate (6α,11β,16β)-21-Chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione BMY-30056 CGP-14458 Uiobetasol Propionate Ultravate Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6-alpha,11-beta,16-beta) | [EINECS(EC#)]
686-247-0 | [Molecular Formula]
C25H31ClF2O5 | [MDL Number]
MFCD00866013 | [Molecular Weight]
484.96 | [MOL File]
66852-54-8.mol |
Chemical Properties | Back Directory | [Melting point ]
213-215°C | [Boiling point ]
570.7±50.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [storage temp. ]
Refrigerator | [solubility ]
Dioxane (Sparingly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
12.55±0.70(Predicted) | [color ]
White to Off-White | [InChIKey]
BDSYKGHYMJNPAB-QNGYMBKVNA-N | [SMILES]
O([C@@]1([C@H](C[C@@]2([H])[C@]3([H])C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C)C(=O)CCl)C(=O)CC |&1:1,2,4,6,9,17,19,21,24,r| | [CAS DataBase Reference]
66852-54-8(CAS DataBase Reference) |
Hazard Information | Back Directory | [Description]
Halobetasol propionate (66852-54-8) is a new ultra-potent topical corticosteroid exhibiting both
antiinflammatory and antihyperplasia properties. The compound is recommended for
the treatment of moderate to severe corticosteroid-responsive dermatoses and appears
to be particularly effective in patients with plaque psoriasis.
| [Chemical Properties]
White Solid | [Originator]
Ciba-Geigy (Switzerland) | [Uses]
Anti-inflammatory; a dermatologic agent commonly used to treat psoriasis | [Definition]
ChEBI: Ulobetasol propionate is a corticosteroid hormone. | [Brand name]
Ultravate (Westwood-Squibb). |
|
|